Rudolf Hanko, CEO of Siegfried, said: “Siegfried is one of the rare suppliers of the pharmaceutical industry that is capable of providing both the chemical synthesis of active pharmaceutical ingredients and production of finished dosage forms. Our new organizational structure will make allowance for this fact. In the future we will be able to convey this attractive offer in a much more effective way.”
Reportedly, the future executive committee of Siegfried will consist of seven members. Rudolf Hanko, CEO, Michael Husler, CFO, and Hanspeter Brun, head of HR, will continue in the same function.
Marianne Spane, formerly head of Siegfried Generics division, will be responsible for business development and sales. Hubert Stuckler, formerly head of the Siegfried actives division, will be responsible for the world-wide technical operations. Former chief communications officer, Peter Gehler, will head the Corporate Center, which includes communication, the legal department, facility management and the chairman’s office.
In addition to his duties as CEO, Rudolf Hanko will assume responsibility for research & development on an interim basis until the position of head of R&D is filled.